1. Immunogenomic Landscape of Hematological Malignancies
- Author
-
Disha Malani, Satu Mustjoki, Olli Lohi, Matti Kankainen, Kirsi J. Granberg, Olli Dufva, Mikko A. I. Keränen, Markus Vähä-Koskela, Merja Heinäniemi, Bishwa Ghimire, Matti Nykter, Sirpa Leppä, Ashwini Kumar, Leo Meriranta, Pirkko Mattila, Petri Pölönen, Juha Mehtonen, Suvi-Katri Leivonen, Krister Wennerberg, Oscar Brück, Jay Klievink, Sanna Siitonen, Jani Huuhtanen, Caroline A. Heckman, Jenni Lahtela, University of Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki, HUS Comprehensive Cancer Center, University of Helsinki, Department of Oncology, University of Helsinki, Medicum, University of Helsinki, Institute for Molecular Medicine Finland, University of Helsinki, HUSLAB, University of Helsinki, Biosciences, University of Helsinki, Krister Wennerberg / Principal Investigator, University of Helsinki, Research Programs Unit, University of Helsinki, Faculty of Medicine, Department of Clinical Chemistry and Hematology, HUS Comprehensive Cancer Center, Department of Oncology, Hematologian yksikkö, TRIMM - Translational Immunology Research Program, Research Programs Unit, Digital Precision Cancer Medicine (iCAN), Medicum, Institute for Molecular Medicine Finland, Precision Systems Medicine, HUSLAB, Biosciences, Krister Wennerberg / Principal Investigator, ATG - Applied Tumor Genomics, Faculty of Medicine, Helsinki University Hospital Area, and Clinicum
- Subjects
0301 basic medicine ,Cancer Research ,Myeloid ,CANCER-TESTIS ANTIGENS ,medicine.medical_treatment ,Epigenesis, Genetic ,0302 clinical medicine ,HLA Antigens ,DNA METHYLATION ,GENE-EXPRESSION ,0303 health sciences ,Myeloid leukemia ,CLASS-II EXPRESSION ,Genomics ,3. Good health ,Gene Expression Regulation, Neoplastic ,Leukemia ,medicine.anatomical_structure ,Oncology ,Leukemia, Myeloid ,030220 oncology & carcinogenesis ,Acute Disease ,Cancer/testis antigens ,Immunotherapy ,Lymphoma, Large B-Cell, Diffuse ,Multiple Myeloma ,TUMOR MICROENVIRONMENT ,3122 Cancers ,Biology ,03 medical and health sciences ,Lymphocytes, Tumor-Infiltrating ,Immune system ,MULTIPLE-MYELOMA ,medicine ,CIITA ,Humans ,030304 developmental biology ,INTERFERON-GAMMA ,Gene Expression Profiling ,Cell Biology ,medicine.disease ,PD-1 BLOCKADE ,Immune checkpoint ,030104 developmental biology ,COMPLEX CLASS-II ,IMMUNE CELLS ,Mutation ,Cancer research ,1182 Biochemistry, cell and molecular biology ,3111 Biomedicine ,Tumor Suppressor Protein p53 - Abstract
Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. We integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings experimentally. Infiltration of cytotoxic lymphocytes was associated with TP53 and myelodysplasia-related changes in acute myeloid leukemia, and activated B cell-like phenotype and interferon-gamma response in lymphoma. CIITA methylation regulating antigen presentation, cancer type-specific immune checkpoints, such as VISTA in myeloid malignancies, and variation in cancer antigen expression further contributed to immune heterogeneity and predicted survival. Our study provides a resource linking immunology with cancer subtypes and genomics in hematological malignancies.
- Published
- 2020
- Full Text
- View/download PDF